Forecast Insight: HIV – Increasing dominance of fixed dose combinations raises bar for single agents
In 2009, HIV antiretroviral sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10.8% between 2005 and 2009.
[USPRwire, Wed Aug 11 2010] ReportsandReports Announce it Will Carry Forecast Insight: HIV – Increasing dominance of fixed dose combinations raises bar for single agents Market Research Report in its Store.
Browse the complete Report on: http://www.reportsandreports.com/market-reports/forecast-insight-hiv-increasing-dominance-of-fixed-dose-combin/
In 2009, HIV antiretroviral sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10.8% between 2005 and 2009. While new cross-class fixed dose combinations will ensure market growth until 2015, Datamonitor expects major patent expiries and rising pressure to reduce healthcare costs to trigger a decline in HIV sales in the second half of the forecast period until 2019.
Scope
• Analysis of the current and future market dynamics for HIV antiretrovirals across the US, 5EU and Japan, supported by insights of key opinion leaders.
• Detailed sales forecasts for the major antiretroviral classes, molecules and brands in each of the seven major markets.
• Thorough assessment of key marketed antiretroviral brands and late stage pipeline products.
• Snapshot of HIV drug sales in the Rest of World by region.
Highlights
In 2009 Atripla replaced Truvada as top-selling antiretroviral in the seven major markets, illustrating the increasing popularity of one-pill-once-a-day treatment regimens. This trend is set to intensify following the launch of Tibotec/J&J/Gilead’s Truvada/rilpivirine and Gilead’s Quad pill from 2012 onwards.
Despite predicting continuously rising sales for Prezista until 2013, Datamonitor expects protease inhibitors overall to see the highest sales loss on a class level over the forecast period due to an empty pipeline and the dominance of cross-class fixed dose combinations.
Datamonitor anticipates the increasing pressure to reduce healthcare costs to lead to more cost-control measurements across the seven major markets, resulting in enhanced possibilities for generics to penetrate the HIV drug market. This, in combination with key patent expiries, will result in a decline of HIV antiretroviral sales from 2016 onwards.
Reasons to Purchase
• Understand the changing market dynamics of HIV drugs, success factors for leading brands and the commercial potential of late stage pipeline products.
• Assess the impact of events such as patent expiries and new product launches on individual brands and the overall HIV antiretroviral market.
• Obtain full country, class and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2010 to 2019.
Browse all Healthcare at http://www.reportsandreports.com/market-research/healthcare/
Browse all Datamonitor at http://www.reportsandreports.com/Publishers/datamonitor
Related Reports:
Forecast Insight: HIV - Cross-class fixed dose combinations drive continued growth
http://www.reportsandreports.com/market-reports/forecast-insight-hiv-cross-class-fixed-dose-combinations-drive/
Forecast Insight: Antihypertensives New fixed dose combinations unable to stem the tide of patent expiries
http://www.reportsandreports.com/market-reports/forecast-insight-antihypertensives-new-fixed-dose-combinations-/
Forecast Insight: Antithrombotics - Market growth dependent on new agents
http://www.reportsandreports.com/market-reports/forecast-insight-antithrombotics-market-growth-dependent-on-ne/
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
